sarpogrelate has been researched along with Diabetes Mellitus, Adult-Onset in 13 studies
sarpogrelate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported." | 9.14 | Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009) |
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 9.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| " We then investigated the effects of 24-month treatment with sarpogrelate hydrochloride, a 5-HT(A2) receptor antagonist, on urinary albumin level in 10 type 2 diabetics with microalbuminuria, compared with not treated control group." | 9.10 | Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. ( Haraguchi, T; Higashi, K; Kobori, S; Koga, N; Minami, J; Takahashi, T; Yano, M, 2002) |
| " Acute and chronic effects of sarpogrelate hydrochloride (sarpogrelate), a 5-HT2 blocker, on glucose tolerance and insulin resistance were examined." | 7.72 | Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. ( Harada, N; Nakaya, Y; Takahashi, A; Takishita, E; Yamato, M; Yoshizumi, M, 2004) |
| "The aim was to evaluate the significance of arteriosclerosis obliterans-related biomarkers in patients with type 2 diabetes mellitus (T2DM), and to compare the effects of sarpogrelate, eicosapentaenoic acid (EPA) and pitavastatin on these markers." | 5.27 | Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study). ( Ito, T; Nomura, S; Okuda, Y; Omoto, S; Shouzu, A; Suzuki, M; Taniura, T, 2018) |
| "8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for 6 months." | 5.24 | Effect of sarpogrelate, a selective 5-HT ( Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ, 2017) |
| "The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported." | 5.14 | Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009) |
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 5.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| " We then investigated the effects of 24-month treatment with sarpogrelate hydrochloride, a 5-HT(A2) receptor antagonist, on urinary albumin level in 10 type 2 diabetics with microalbuminuria, compared with not treated control group." | 5.10 | Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. ( Haraguchi, T; Higashi, K; Kobori, S; Koga, N; Minami, J; Takahashi, T; Yano, M, 2002) |
| " Acute and chronic effects of sarpogrelate hydrochloride (sarpogrelate), a 5-HT2 blocker, on glucose tolerance and insulin resistance were examined." | 3.72 | Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. ( Harada, N; Nakaya, Y; Takahashi, A; Takishita, E; Yamato, M; Yoshizumi, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nomura, S | 2 |
| Taniura, T | 1 |
| Shouzu, A | 2 |
| Omoto, S | 2 |
| Suzuki, M | 1 |
| Okuda, Y | 1 |
| Ito, T | 1 |
| Yoo, H | 1 |
| Park, I | 1 |
| Kim, DJ | 1 |
| Lee, S | 1 |
| Nagayama, D | 1 |
| Ohira, M | 1 |
| Saiki, A | 1 |
| Shirai, K | 1 |
| Tatsuno, I | 1 |
| Lee, DH | 1 |
| Chun, EJ | 1 |
| Hur, JH | 1 |
| Min, SH | 1 |
| Lee, JE | 1 |
| Oh, TJ | 1 |
| Kim, KM | 1 |
| Jang, HC | 1 |
| Han, SJ | 1 |
| Kang, DK | 1 |
| Kim, HJ | 1 |
| Lim, S | 1 |
| Shinohara, Y | 1 |
| Nishimaru, K | 1 |
| Iizuka, K | 1 |
| Hamaue, N | 1 |
| Machida, T | 1 |
| Hirafuji, M | 1 |
| Tsuji, M | 1 |
| Park, SY | 1 |
| Rhee, SY | 1 |
| Oh, S | 1 |
| Kwon, HS | 1 |
| Cha, BY | 1 |
| Lee, HJ | 1 |
| Lee, HC | 1 |
| Kim, YS | 1 |
| Takahashi, T | 2 |
| Yano, M | 1 |
| Minami, J | 1 |
| Haraguchi, T | 1 |
| Koga, N | 1 |
| Higashi, K | 1 |
| Kobori, S | 1 |
| Yamakawa, J | 1 |
| Itoh, T | 1 |
| Kusaka, K | 1 |
| Kawaura, K | 1 |
| Wang, XQ | 1 |
| Kanda, T | 1 |
| Takishita, E | 1 |
| Takahashi, A | 1 |
| Harada, N | 1 |
| Yamato, M | 1 |
| Yoshizumi, M | 1 |
| Nakaya, Y | 1 |
| Nishikawa, M | 1 |
| Iwasaka, T | 1 |
| Ogawa, S | 1 |
| Mori, T | 1 |
| Nako, K | 1 |
| Ishizuka, T | 1 |
| Ito, S | 1 |
| Pietraszek, MH | 1 |
| Takada, Y | 1 |
| Taminato, A | 1 |
| Yoshimi, T | 1 |
| Watanabe, I | 1 |
| Takada, A | 1 |
7 trials available for sarpogrelate and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study).
Topics: Adiponectin; Aged; Aged, 80 and over; Ankle Brachial Index; Arteriosclerosis Obliterans; Biomarkers; | 2018 |
Effect of sarpogrelate, a selective 5-HT
Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomograph | 2017 |
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
Topics: Aged; Aspirin; Cerebral Infarction; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-U | 2009 |
Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Ankle Brachial Index; Aspirin; Biomarkers; C-Reactive Protein; Carotid Int | 2012 |
Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glycated | 2002 |
A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans.
Topics: Adiponectin; Aged; Arteriosclerosis Obliterans; Diabetes Mellitus, Type 2; Female; Humans; Intercell | 2003 |
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Ch | 2008 |
6 other studies available for sarpogrelate and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of sarpogrelate on microvascular complications with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathie | 2019 |
Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients.
Topics: Aged; Ankle Brachial Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relation | 2014 |
Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.
Topics: Abdominal Fat; Adipocytes; Animals; Blood Glucose; Cell Count; Diabetes Mellitus, Type 2; Disease Mo | 2009 |
Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Insulin Resistan | 2004 |
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Topics: Adiponectin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Fe | 2005 |
The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus.
Topics: Adult; Aged; Collagen; Diabetes Mellitus, Type 2; Female; Humans; Ketanserin; Male; Middle Aged; Pla | 1993 |